What is Human Metapneumovirus (hMPV)
Human Metapneumovirus (hMPV) is a prevalent respiratory virus that infects individuals across all age groups. It is responsible for a range of respiratory illnesses, from mild, cold-like symptoms to severe lower respiratory tract infections (LRTIs), especially in vulnerable populations such as young children, the elderly, and immunocompromised individuals. First identified in 2001 in the Netherlands, hMPV has since become a recognized cause of respiratory disease worldwide.
Key Characteristics of hMPV Virus
Classification:
- Family: Paramyxoviridae
- Subfamily: Pneumovirinae (which also includes Respiratory Syncytial Virus (RSV))
- Genus: Metapneumovirus
- Type: Enveloped, single-stranded, negative-sense RNA virus.
Structure:
hMPV has a spherical virion, approximately 150-200 nm in diameter. Its envelope contains several glycoproteins, including Fusion (F), Attachment (G), Small Hydrophobic (SH), and Matrix (M2-1). These proteins are involved in the virus's ability to infect host cells and evade immune detection.
Genome:
The viral genome is about 13 kilobases (kb) in length and encodes for 9 major proteins, which play crucial roles in replication and immune evasion.
Subtypes:
hMPV is classified into two major subgroups (A and B), each with two genetic lineages (A1, A2; B1, B2). These subgroups circulate concurrently and show seasonal variations, but both cause similar illnesses.
Epidemiology
Discovery and Global Distribution:
hMPV was first identified in 2001 in children with respiratory infections in the Netherlands. Retrospective studies suggest the virus was circulating long before its official discovery. It is now recognized worldwide, with cases reported across all continents.
Seasonality:
hMPV is primarily seasonal, circulating in late winter and early spring in temperate climates, similar to RSV and influenza. In tropical regions, however, it can circulate year-round, often peaking during the rainy season.
Transmission:
The virus is transmitted primarily via respiratory droplets from coughing, sneezing, or talking. It can also spread through direct contact (e.g., handshakes) and contaminated surfaces (fomites). Transmission is highly efficient, especially in households and daycare centers, with 40-70% of household contacts potentially becoming infected after exposure.
Age Distribution:
- Children: Infants and young children (under 5 years) are the most affected group. Nearly all children are infected by hMPV by the age of 5. It is a leading cause of bronchiolitis and pneumonia in this group.
- Adults: While reinfection occurs throughout life, adults typically experience milder illness. However, older adults (65 years and older) and immunocompromised individuals are at risk for more severe disease.
What are the Symptoms of HMPV
hMPV causes a broad spectrum of respiratory symptoms, ranging from mild to severe. These symptoms often overlap with those caused by RSV, rhinovirus, and influenza.
-
Upper Respiratory Tract Infection (URTI - Most Common):
- Runny or stuffy nose
- Sore throat
- Cough
- Mild fever
- Headache
These symptoms are typically mild and last for 5-10 days, resembling those of the common cold.
-
Lower Respiratory Tract Infection (LRTI - More Severe):
- Bronchiolitis (especially in infants): Characterized by cough, wheeze, rapid breathing, and respiratory distress. It is a leading cause of bronchiolitis alongside RSV.
- Pneumonia: Symptoms include fever, cough, chest pain, and difficulty breathing. Pneumonia caused by hMPV may require hospitalization.
- Bronchitis: Involves a persistent cough and mucus production.
- Exacerbation of Chronic Lung Diseases: Conditions like asthma and chronic obstructive pulmonary disease (COPD) may worsen in response to hMPV infection.
- Croup: Though less common than with parainfluenza viruses, croup can also occur with hMPV.
-
Severity
- Mild: Healthy children and adults typically experience self-limiting illness.
- Moderate to Severe: More severe disease occurs in infants under 6 months, elderly individuals, and those with weakened immune systems. Severe cases may require hospitalization, ICU care, or mechanical ventilation. In rare cases, hMPV infection can be fatal, especially in high-risk groups.
What is the Diagnosis for HMPV?
Diagnosing hMPV involves clinical evaluation, but definitive diagnosis requires laboratory testing:
- RT-PCR (Reverse Transcription Polymerase Chain Reaction): The gold standard for detection, RT-PCR is highly sensitive and specific. It detects viral RNA from samples like nasopharyngeal swabs or sputum.
- Antigen Detection Tests: Rapid tests that detect viral proteins. These are less sensitive than RT-PCR but can provide quicker results.
- Serology (Antibody Tests): Used mainly in epidemiological studies or to confirm past infection in immunocompromised patients. Not suitable for acute diagnosis due to delayed antibody production.
- Viral Culture: Rarely used in clinical settings due to slow results and lower sensitivity.
What Is the Treatment for HMPV Infection
Currently, there are no specific antiviral treatments for hMPV. Management is primarily supportive:
- Hydration: Ensuring adequate fluid intake is essential, particularly for infants and young children.
- Fever/Pain Relief: Over-the-counter medications like acetaminophen or ibuprofen may be used to manage fever and discomfort.
- Oxygen Therapy: Administered to patients with low oxygen levels, particularly in hospitalized cases of LRTI.
- Mechanical Ventilation: In severe cases of respiratory failure, particularly in high-risk groups.
- Management of Underlying Conditions: Optimizing the care of individuals with chronic conditions like asthma or COPD.
How to Prevent HMPV Infection
Currently, no vaccine is available for hMPV. However, several vaccine candidates are in development, including subunit, viral vector, and mRNA-based vaccines. In the absence of a vaccine, prevention relies on general infection control measures:
- Hand Hygiene: Frequent handwashing with soap and water or alcohol-based hand sanitizers.
- Respiratory Etiquette: Cough and sneeze into tissues or elbows, and dispose of tissues promptly.
- Avoid Close Contact: Stay away from individuals who are sick, especially those in high-risk groups.
- Surface Cleaning: Regularly disinfect high-touch surfaces to minimize the spread.
- Isolation: Infected individuals, particularly those in high-risk groups or healthcare settings, should limit contact during the contagious period, which typically lasts from 1-3 days before symptom onset until symptoms resolve (usually around 7-10 days).
Importance & Impact
hMPV is a significant global cause of respiratory infections, contributing to 3-11% of all acute respiratory infections in children. It is second only to RSV as a cause of bronchiolitis and pneumonia in young children. In adults, particularly those over 65 years and immunocompromised individuals, hMPV is a major cause of hospitalization for respiratory illness.
Despite its prevalence, hMPV is often underestimated or misdiagnosed as a common cold or another respiratory virus, as its symptoms are similar to those of other infections like RSV and influenza. Specific testing is essential for accurate diagnosis and proper management.
Conclusion
Human Metapneumovirus (hMPV) is a widespread respiratory virus that poses significant health risks, particularly to vulnerable populations such as young children, older adults, and immunocompromised individuals. While there is no specific antiviral treatment or vaccine currently available, supportive care and infection control measures can help manage the disease and prevent transmission. Ongoing research into vaccines and antivirals is crucial to improving outcomes and reducing the impact of this virus globally.
